Beyond considering single-agent treatment with a YAP/TAZ/TEAD inhibitor, positioning such therapeutics alongside standard-of-care treatments may present an optimal choice, given the role of downstream Hippo pathway signalling in driving resistance to a variety of anti-cancer drugs [265]. Here, YAP1 is linked to cancer.